Access and reimbursement
Receive assistance with access and reimbursement
Kyowa Kirin Cares helps to get your patients from prescription to therapy quickly and seamlessly. Once you enroll, an oncology nurse will assist your patients with access and reimbursement options. The process is simple:
Through Kyowa Kirin Cares, access options are available for patients
A Kyowa Kirin Cares oncology nurse can help your patients navigate their access options—regardless of their insurance coverage.
Kyowa Kirin offers co-pay assistance for eligible commercially insured patients. Review the co-pay assistance terms and conditions to determine if your patients with commercial insurance qualify. a,b
In most cases, Kyowa Kirin does not offer a program for patients with government or military insurance.c A nurse may be able to refer these patients to independent charitable foundations and/or educate them on federal plan selections.
Kyowa Kirin offers a Patient Assistance Program for eligible uninsured patients.c Download the application to review the terms and conditions and determine if your patients without insurance qualify.d
aPatients must be US residents with an active primary commercial plan; patients with federal or state government insurance such as Medicare, Medicaid, and Tricare are not eligible for co-pay assistance. Other terms and conditions may apply.
bCommercially insured patients do not need to participate in Kyowa Kirin Cares to be eligible for co-pay assistance.
cPatients who do not meet the Patient Assistance Program coverage criteria and have special circumstances of financial and/or medical hardship, as determined in accordance with Kyowa Kirin Cares criteria, can request that an exception be made for them. The decision to grant an exception is based on an individual's unique circumstances and is made solely at the discretion of Kyowa Kirin.
dPatients must be US residents with no active medical or pharmacy benefit insurance and an annual gross income ≤400% of the federal poverty level, confirmed by electronic income verification response or documented proof of income.
Connect your patients with ongoing support
Kyowa Kirin Cares partners with you to provide your patients with personalized and ongoing support throughout their journeys with POTELIGEO. A dedicated oncology nurse will be available to:
Answer questions about the infusion experience
Answer general questions about POTELIGEO
Provide external resources, when applicable
Help patients manage barriers to adherence
By enrolling in Kyowa Kirin Cares, you're providing a resource to your patients, especially those requiring financial assistance. However, if you choose not to enroll in Kyowa Kirin Cares, your patients can enroll on their own to take advantage of ongoing support from an oncology nurse.
The information provided by the oncology nurse to your patients is for informational purposes only and does not constitute medical advice. It is not intended to replace a discussion between you and your patient. All decisions regarding patient care must be made by a patient's healthcare provider considering the unique characteristics of each patient.
Get your hands on important forms and resources
Access Kyowa Kirin Cares forms as well as useful Poteligeo information and resources.
Download the Kyowa Kirin Cares prescription and enrollment form to get enrolled.
Download the Patient Assistance Program application for your uninsured patients.
Visit the POTELIGEO website to learn about efficacy, safety, dosing, and more.
Download and use this template letter of medical necessity for appropriate patient cases.
Download and use this appeal template letter for your patients who have been denied coverage.
POTELIGEO® (mogamulizumab-kpkc) injection for intravenous infusion is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
Important Safety Information
Warnings and Precautions:
Dermatologic toxicity: Monitor patients for rash throughout the course of treatment. For patients who experienced dermatologic toxicity in Trial 1, the median time to onset was 15 weeks, with 25% of cases occurring after 31 weeks. Interrupt Poteligeo for moderate or severe rash (Grades 2 or 3). Permanently discontinue Poteligeo for life-threatening (Grade 4) rash or for any SJS or TEN.
Infusion reactions: Most infusion reactions occur during or shortly after the first infusion. Infusion reactions can also occur with subsequent infusions. Monitor patients closely for signs and symptoms of infusion reactions and interrupt the infusion for any grade reaction and treat promptly. Permanently discontinue Poteligeo for any life-threatening (Grade 4) infusion reaction.
Infections: Monitor patients for signs and symptoms of infection and treat promptly.
Autoimmune complications: Interrupt or permanently discontinue POTELIGEO as appropriate for suspected immune-mediated adverse reactions. Consider the benefit/risk of POTELIGEO in patients with a history of autoimmune disease.
Complications of allogeneic HSCT after Poteligeo: Increased risks of transplant complications have been reported in patients who received allogeneic HSCT after POTELIGEO. Follow patients closely for early evidence of transplant-related complications.
The most common adverse reactions (reported in ≥ 10% of patients) with Poteligeo in the clinical trial were infusion reaction (33%), fatigue (31%), diarrhea (28%), drug eruption (24%), upper respiratory tract infection (22%), musculoskeletal pain (22%), skin infection (19%), pyrexia (17%), edema (16%), nausea (16%), headache (14%), thrombocytopenia (14%), constipation (13%), anemia (12%), mucositis (12%), rash (11%), cough (11%), and hypertension (10%).
Please see full Prescribing Information.